UniProt O96013 · PDB · AlphaFold · Substrate: PAKtide · Clone: Catalytic (aa 295-591)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Gilteritinib | 85.4% | 14.6% | 88.97 | 0.506 |
| 2 | Pacritinib | 81.1% | 18.9% | 88.64 | 0.452 |
| 3 | Defactinib | 81.0% | 19.0% | 92.68 | 0.450 |
| 4 | Pralsetinib | 77.4% | 22.6% | 93.43 | 0.643 |
| 5 | Brigatinib | 66.6% | 33.4% | 82.96 | 0.513 |
| 6 | Fostamatinib | 56.4% | 43.6% | 96.74 | 0.613 |
| 7 | Capivasertib | 51.6% | 48.4% | 96.48 | 0.644 |
| 8 | Axitinib | 39.3% | 60.7% | 93.23 | 0.688 |
| 9 | Repotrectinib | 35.1% | 64.9% | 84.21 | 0.608 |
| 10 | Rabusertib | 29.0% | 71.0% | 98.74 | 0.687 |
| 11 | Fedratinib | 28.5% | 71.5% | 96.21 | 0.576 |
| 12 | Sunitinib | 27.5% | 72.5% | 91.73 | 0.524 |
| 13 | Entrectinib | 25.6% | 74.4% | 93.69 | 0.671 |
| 14 | Paxalisib | 22.5% | 77.5% | 99.75 | 0.609 |
| 15 | Darovasertib | 21.6% | 78.4% | 96.99 | 0.719 |
| 16 | Dabrafenib | 18.6% | 81.4% | 94.74 | 0.633 |
| 17 | Ruxolitinib | 18.5% | 81.5% | 98.25 | 0.592 |
| 18 | Baricitinib | 18.4% | 81.6% | 97.99 | 0.616 |
| 19 | Alpelisib | 17.9% | 82.1% | 97.22 | 0.720 |
| 20 | Neratinib | 17.3% | 82.7% | 93.18 | 0.597 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.36
- Epithelial log2(TPM+1): 4.89
- Fold change: -0.52
- Status: No significant change
Selectivity landscape vs inhibition on PAK4
Each point is one of the 92 approved drugs; color = inhibition % on PAK4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…